within Pharmacolibrary.Drugs.ATC.N;

model N07BC05
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 2e-06,
    adminDuration  = 600,
    adminMass      = 40 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.004,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0009166666666666666,
    Tlag           = 600,            
    Vdp             = 0.016,
    k12             = 0.2,
    k21             = 0.2
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>N07BC05</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Levomethadone is the levorotatory (R)-enantiomer of methadone and acts as a full opioid agonist, primarily at the mu-opioid receptor. It is used in opioid substitution therapy, particularly in the management of opioid dependence, and sometimes for chronic pain. Its use is approved in several European countries, but not in the US where racemic methadone is more commonly used.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters estimated for a typical adult population, based primarily on known PK parameters for racemic methadone with consideration of the higher activity and potentially different kinetics of the (R)-enantiomer. No specific, publication-referenced PK data available for levomethadone.</p><h4>References</h4><ol><li><p>Blume, HH, et al., &amp; Schug, B (2015). Relative bioavailability of a newly developed 5-mg levomethadone hydrochloride IR tablet (L-Polamidon® 5 mg tablets) in comparison with the 5-mg levomethadone hydrochloride oral solution (L-Polamidon® solution for substitution) as reference product. <i>International journal of clinical pharmacology and therapeutics</i> 53(4) 335–344. DOI:<a href=&quot;https://doi.org/10.5414/CP202180&quot;>10.5414/CP202180</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25669614/&quot;>https://pubmed.ncbi.nlm.nih.gov/25669614</a></p></li><li><p>Lötsch, J, et al., &amp; Geisslinger, G (2006). Modulation of the central nervous effects of levomethadone by genetic polymorphisms potentially affecting its metabolism, distribution, and drug action. <i>Clinical pharmacology and therapeutics</i> 79(1) 72–89. DOI:<a href=&quot;https://doi.org/10.1016/j.clpt.2005.09.010&quot;>10.1016/j.clpt.2005.09.010</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16413243/&quot;>https://pubmed.ncbi.nlm.nih.gov/16413243</a></p></li><li><p>Schall, U, et al., &amp; Gastpar, M (1996). Pharmacokinetic and pharmacodynamic interactions in an outpatient maintenance therapy of intravenous heroin users with levomethadone. <i>Addiction biology</i> 1(1) 105–113. DOI:<a href=&quot;https://doi.org/10.1080/1355621961000124736&quot;>10.1080/1355621961000124736</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12893491/&quot;>https://pubmed.ncbi.nlm.nih.gov/12893491</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end N07BC05;
